[Pubmed] Immune checkpoint inhibitor cardiomyotoxicity: a case series of five patients and development of a clinical man
Posté : 29 avr. 2026 12:00
Intern Med J. 2026 Apr 29. doi: 10.1111/imj.70368. Online ahead of print.
ABSTRACT
Immune checkpoint inhibitor (ICI) therapies have revolutionised the management of a range of malignancies. However, the syndrome of ICI induced cardiomyotoxicity, also reported as triple "M" syndrome (myasthenia gravis, myositis and myocarditis) is an unfortunate severe consequence in up to 1%-2% of patients receiving ICI, with an associated mortality of up to 50%. Based on international evidence and local experience, we have developed a clinical pathway in our institution as a guide to the early identification and targeted management of this condition.
PMID:42052862 | DOI:10.1111/imj.70368
Source: https://pubmed.ncbi.nlm.nih.gov/4205286 ... t6+133c1fe